This post was originally published on this site
Massachusetts-based Moderna, Inc. (MRNA) develops transformative medicines based on messenger ribonucleic acid (mRNA). With its EUA from the U.S. FDA for its COVID-19 vaccine in hand, the company recently announced its plans to expand the size of clinical trial testing of its COVID-19 vaccine in children aged between five and 11 years.
Because the highly contagious Delta variant continues to spread at an alarming pace, COVID-19 vaccine stocks are again coming into focus with investors. According to CDC data, 70% of adults in the U.S. have received at least one dose of COVID-19 vaccine. However, with the spread of the Delta variant, the United States could see 140,000 new cases per day by the end of this month. And because most countries are seeking achieve herd immunity as soon as possible, both AZN and MRNA should benefit.
